ATE522218T1 - Dosierungseinheit enthaltend prostaglandin-analog zur behandlung von darmverstopfung - Google Patents

Dosierungseinheit enthaltend prostaglandin-analog zur behandlung von darmverstopfung

Info

Publication number
ATE522218T1
ATE522218T1 AT02780083T AT02780083T ATE522218T1 AT E522218 T1 ATE522218 T1 AT E522218T1 AT 02780083 T AT02780083 T AT 02780083T AT 02780083 T AT02780083 T AT 02780083T AT E522218 T1 ATE522218 T1 AT E522218T1
Authority
AT
Austria
Prior art keywords
intestinal
constitution
treatment
dosage unit
unit containing
Prior art date
Application number
AT02780083T
Other languages
English (en)
Inventor
Ryuji Ueno
Myra Patchen
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23293447&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE522218(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Application granted granted Critical
Publication of ATE522218T1 publication Critical patent/ATE522218T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/23—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen containing rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
AT02780083T 2001-11-14 2002-11-14 Dosierungseinheit enthaltend prostaglandin-analog zur behandlung von darmverstopfung ATE522218T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33131601P 2001-11-14 2001-11-14
PCT/JP2002/011862 WO2003041716A1 (en) 2001-11-14 2002-11-14 Dosage unit comprising a prostaglandin analog for treating constipation

Publications (1)

Publication Number Publication Date
ATE522218T1 true ATE522218T1 (de) 2011-09-15

Family

ID=23293447

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02780083T ATE522218T1 (de) 2001-11-14 2002-11-14 Dosierungseinheit enthaltend prostaglandin-analog zur behandlung von darmverstopfung

Country Status (15)

Country Link
US (3) US8097653B2 (de)
EP (2) EP1443938B1 (de)
JP (2) JP4852229B2 (de)
AR (3) AR037524A1 (de)
AT (1) ATE522218T1 (de)
BR (1) BR0214075A (de)
CA (1) CA2464420C (de)
CY (1) CY1115856T1 (de)
DK (2) DK2298314T3 (de)
ES (2) ES2368729T3 (de)
HK (1) HK1155649A1 (de)
LU (1) LU92826I2 (de)
PT (2) PT1443938E (de)
TW (1) TWI331920B (de)
WO (1) WO2003041716A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
PT1562604E (pt) * 2002-10-23 2012-04-09 Sucampo Ag Compostos de prostaglandina para o tratamento de obesidade
EP1575596B1 (de) * 2002-12-27 2016-06-22 Sucampo AG Prostaglandinderivate zur behandlung von reizdarmsyndrom und/oder funktionellen dyspepsie
ATE489096T1 (de) * 2003-07-03 2010-12-15 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
TWI387454B (zh) * 2004-09-02 2013-03-01 Sucampo Ag 治療胃腸道疾病之方法及組成物
CN104248763A (zh) * 2005-03-07 2014-12-31 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
CA2602812C (en) * 2005-04-12 2014-11-18 Sucampo Ag Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
PT1978944E (pt) * 2006-01-24 2012-11-26 Sucampo Ag Formulação em cápsula de gelatina mole
MX2008009652A (es) * 2006-01-24 2008-11-06 R Tech Ueno Ltd Composicion farmaceutica que comprende un compuesto biciclico y metodo para estabilizar el compuesto biciclico.
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
BR112012006069A8 (pt) * 2009-09-18 2017-10-10 Adolor Corp Método para tratar ou prevenir constipação induzida e disfunção intestinal induzida por opióide em um humano, e, uso de uma quantidade terapeuticamente efetiva de composto
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5350141A (en) * 1976-10-18 1978-05-08 Ono Pharmaceut Co Ltd Stabilization of prostaglandin and prostaglandin analogues
GB1581886A (en) 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
GB2210556B (en) * 1987-10-02 1991-07-17 Ueno Seiyaku Oyo Kenkyujo Kk The use of 15-keto-16-halo-prostaglandins in cathartic compositions
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
CA2030344C (en) * 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
CA2030346C (en) * 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
ATE174221T1 (de) * 1990-05-01 1998-12-15 R Tech Ueno Ltd Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten
CA2046069C (en) * 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
JP2938579B2 (ja) * 1990-12-15 1999-08-23 株式会社上野製薬応用研究所 消化管壁保護剤
ES2093774T3 (es) * 1991-03-14 1997-01-01 R Tech Ueno Ltd Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina.
EP0554794B1 (de) * 1992-02-04 1998-07-29 Eisai Co., Ltd. Aminobenzoesäure Derivate
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
DK0857718T3 (da) * 1996-06-10 2002-12-16 Sucampo Ag Endothelinantagonist
DE19717005A1 (de) * 1997-04-23 1998-10-29 Kennametal Inc Spannfutter für Rundlaufwerkzeuge
CN1206997C (zh) 1997-11-28 2005-06-22 株式会社·R-技术上野 内皮缩血管肽拮抗剂
US6492417B1 (en) 1997-12-22 2002-12-10 Alcon Manufacturing, Ltd. 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
DE60010913T2 (de) * 1999-10-15 2005-06-09 Sucampo Ag Bizyklische Verbindungen, Zusammenstellung und Verfahren zu ihrer Stabilisierung
DE60139002D1 (de) 2000-04-06 2009-07-30 Sucampo Ag Gallensäurefördernde zusammensetzung für lebertransplantation welche ein 15-keto prostaglandin enthält
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
DE60225266T2 (de) 2001-05-18 2009-03-19 Sucampo Ag Zusammensetzung mit induzierendem kathartischen effekt
JP4786866B2 (ja) 2001-08-31 2011-10-05 スキャンポ・アーゲー クロライドチャンネルオープナーとしてのプロスタグランジンアナログ
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US7732487B2 (en) 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
EP1575596B1 (de) 2002-12-27 2016-06-22 Sucampo AG Prostaglandinderivate zur behandlung von reizdarmsyndrom und/oder funktionellen dyspepsie

Also Published As

Publication number Publication date
US20120088824A1 (en) 2012-04-12
TW200300091A (en) 2003-05-16
JP4852229B2 (ja) 2012-01-11
ES2524369T3 (es) 2014-12-05
DK2298314T3 (en) 2014-12-01
PT1443938E (pt) 2011-09-27
EP2298314A1 (de) 2011-03-23
US20030119898A1 (en) 2003-06-26
ES2368729T3 (es) 2011-11-21
AR037524A1 (es) 2004-11-17
CA2464420C (en) 2011-12-13
JP2005513014A (ja) 2005-05-12
PT2298314E (pt) 2014-12-03
TWI331920B (en) 2010-10-21
WO2003041716A1 (en) 2003-05-22
HK1155649A1 (en) 2012-05-25
CY1115856T1 (el) 2017-01-25
EP1443938B1 (de) 2011-08-31
BR0214075A (pt) 2004-09-28
DK1443938T3 (da) 2011-09-26
AR117404A2 (es) 2021-08-04
EP2298314B1 (de) 2014-09-03
LU92826I2 (fr) 2015-11-24
US8389542B2 (en) 2013-03-05
AR098997A2 (es) 2016-06-22
US20130143958A1 (en) 2013-06-06
CA2464420A1 (en) 2003-05-22
JP2011201905A (ja) 2011-10-13
EP1443938A1 (de) 2004-08-11
US8097653B2 (en) 2012-01-17

Similar Documents

Publication Publication Date Title
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE417606T1 (de) Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
DE60232251D1 (de) Pharmazeutische zusammensetzungen zur behandlung von asthma
DE60320007D1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
DE69940131D1 (de) Mittel zur Behandlung von Erkrankungen der Speiseröhre
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
DE60142473D1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
DE60328476D1 (de) Medizinisches ballonsystem zur behandlung von adipositas
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60022916D1 (de) Reboxetin zur Behandlung von peripheren Neuropathien
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
ATE522218T1 (de) Dosierungseinheit enthaltend prostaglandin-analog zur behandlung von darmverstopfung
ATE292134T1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
ATE384522T1 (de) Medikamente zur chemotherapeutischen behandlung von erkrankungen
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE60027209D1 (de) Arzneimittel enthaltend hydroxyapatite zur behandlung von knochengewebserkrankungen
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
DE60218375D1 (de) Pharmazeutische Zusammensetzung zur Behandlung gynäkologischer Erkrankungen
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1443938

Country of ref document: EP